The Role of Selective Estrogen Receptor Modulators in the Prevention of Breast Cancer: Comparison of the Clinical Trials

Oncologist

Volumn 9, Issue 2, 2004, Pages 116-125

  Martino, Silvana ^a   Costantino, Joseph ^b   McNabb, Michelle ^c   Mershon, John ^c   Bryant, Katherine ^c   Powles, Trevor ^d   Secrest, Roberta J ^c  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c ELI LILLY AND COMPANY   (United States)

^d INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Breast cancer; Chemoprevention; Raloxifene; Selective estrogen receptor modulators; Tamoxifen

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

BREAST CANCER; BREAST CARCINOGENESIS; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; CATARACT; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; ENDOMETRIAL DISEASE; ENDOMETRIUM CANCER; FLU LIKE SYNDROME; FRAGILITY FRACTURE; HIGH RISK POPULATION; HOT FLUSH; HUMAN; LEG CRAMP; PERIPHERAL EDEMA; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; STROKE; VENOUS THROMBOEMBOLISM;

ADULT; AGED; ANTICARCINOGENIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS; FEMALE; HUMANS; MIDDLE AGED; RALOXIFENE; RISK ASSESSMENT; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN;

EID: 1842557428     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.9-2-116     Document Type: Review

References (47)

1. Jemal A, Murray T, Samuels A et al. Cancer statistics, 2003. CA Cancer J Clin 2003;53:5-26.
2. Ferlay J, Bray F, Pisani P et al. Globocan 2000: Cancer Incidence, Mortality, and Prevalence Worldwide, Version 1.0. Lyon: IARC Cancer Base No. 5. IARC Press, 2001.
3. Nolvadex® (tamoxifen citrate) [package insert]. Wilmington, DE: Zeneca Pharmaceuticals, 1998.
4. Evista® [package insert]. Indianapolis, IN: Eli Lilly and Company, 2001.
5. Mosca L, Barrett-Connor E, Wenger NK et al. Design and methods of the Raloxifene Use for The Heart (RUTH) study. Am J Cardiol 2001;88:392-395.
6. Wenger NK, Barrett-Connor E, Collins P et al. Baseline characteristics of participants in the Raloxifene Use for The Heart (RUTH) trial. Am J Cardiol 2002;90:1204-1210.
7. Clemons M, Goss P. Estrogen and the risk of breast cancer. N Engl J Med 2001;344:276-285.
8. Toniolo PG, Levitz M, Zeleniuch-Jacquotte A et al. A prospective study of endogenous estrogens and breast cancer in postmenopausal women. J Natl Cancer Inst 1995;87:190-197.
9. Thomas HV, Key TJ, Allen DS et al. A prospective study of endogenous serum hormone concentrations and breast cancer risk in post-menopausal women on the island of Guernsey. Br J Cancer 1997;76:401-405.
10. Cauley JA, Lucas FL, Kuller LH et al. Elevated serum estradiol and testosterone concentrations are associated with a high risk for breast cancer. Study of Osteoporotic Fractures Research Group. Ann Intern Med 1999;130:270-277.
11. Hankinson SE, Willett WC, Manson JE et al. Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 1998;90:1292-1299.
12. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997;350:1047-1059.
13. Magnusson C, Baron JA, Correia N et al. Breast-cancer risk following long-term oestrogen- and oestrogen-progestin-replacement therapy. Int J Cancer 1999;81:339-344.
14. Colditz GA, Hankinson SE, Hunter DJ et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995;332:1589-1593.
15. Hulka BS. Epidemiologic analysis of breast and gynecologic cancers. Prog Clin Biol Res 1997;396:17-29.
16. Madigan MP, Ziegler RG, Benichou J et al. Proportion of breast cancer cases in the United Sates explained by well-established risk factors. J Natl Cancer Inst 1995;87:1681-1685.
17. Ramon JM, Escriba JM, Casas I et al. Age at first full-term pregnancy, lactation and parity and risk of breast cancer: a case-control study in Spain. Eur J Epidemiol 1996;12:449-453.
18. Lambe M, Hsieh CC, Chan HW et al. Parity, age at first and last birth, and risk of breast cancer: a population-based study in Sweden. Breast Cancer Res Treat 1996;38:305-311.
19. Schairer C, Persson I, Falkeborn M et al. Breast cancer risk associated with gynecologic surgery and indications for such surgery. Int J Cancer 1997;70:150-154.
20. Meijer WJ, van Lindert AC. Prophylactic oophorectomy. Eur J Obstet Gynecol Reprod Biol 1992;47:59-65.
21. Thomas HV, Key TJ, Allen DS et al. Re: reversal of relation between body mass and endogenous estrogen concentrations with menopausal status. J Natl Cancer Inst 1997;89:396-398.
22. Cauley JA, Gutai JP, Sandler RB et al. The relationship of endogenous estrogen to bone density and bone area in normal postmenopausal women. Am J Epidemiol 1986;124:752-761.
23. Zhang Y, Kiel DP, Kreger BE et al. Bone mass and the risk of breast cancer among postmenopausal women. N Engl J Med 1997;336:611-617.
24. Fisher B, Costantino JP, Wickerham DL et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-1388.
25. Cohen FJ, Watts S, Shah A et al. Uterine effects of three-year raloxifene therapy in postmenopausal women younger than age 60. Obstet Gynecol 2000;95:104-110.
26. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998;351:1451-1467.
27. Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med 1998;339:1609-1618.
28. Gail MH, Brinton LA, Byar DP et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989;81:1879-1886.
29. Veronesi U, Maisonneuve P, Costa A et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet 1998;352:93-97.
30. Veronesi U, Maisonneuve P, Sacchini V et al. Tamoxifen for breast cancer among hysterectomised women. Lancet 2002;359:1122-1124.
31. Veronesi U, Maisonneuve P, Rotmensz N et al. Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women. J Natl Cancer Inst 2003;95:160-165.
32. Powles T, Eeles R, Ashley S et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 1998;352:98-101.
33. Cuzick J, Powles T, Veronesi U et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet 2003;361:296-300.
34. Cuzick J, Forbes J, Edwards R et al. First results from the International Breast Cancer Intervention Study (IB1S-I): a randomised prevention trial. Lancet 2002;360:817-824.
35. Ettinger B, Black DM, Mitlak BH et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 1999;282:637-645.
36. Cummings SR, Eckert S, Krueger KA et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. JAMA 1999;281:2189-2197.
37. Cauley JA, Norton L, Lippman ME et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Breast Cancer Res Treat 2001;65:125-134.
38. Cohen FJ, Lu Y. Characterization of hot flashes reported by healthy postmenopausal women receiving raloxifene or placebo during osteoporosis prevention trials. Maturitas 2000;34:65-73.
39. Hulley S, Grady D, Bush T et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-613.
40. Ciaccia AV, Zhou L, Moscarelli E et al. The effect of raloxifene therapy on the incidence of cataracts on osteoporotic postmenopausal women: 4-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) trial. J Am Geriatr Soc 2001;49:S152.
41. Vogel VG, Costantino JP, Wickerham DL et al. The study of tamoxifen and raloxifene: preliminary enrollment data from a randomized breast cancer risk reduction trial. Clin Breast Cancer 2002;3:153-159.
42. Vogel VG, Costantino JP, Wickerham DL et al. National surgical adjuvant breast and bowel project update: prevention trials and endocrine therapy of ductal carcinoma in situ. Clin Cancer Res 2003;9:495S-501S.
43. Cauley JA, Lucas FL, Kuller LH et al. Bone mineral density and risk of breast cancer in older women: the study of osteoporotic fractures. Study of Osteoporotic Fractures Research Group. JAMA 1996;276:1404-1408.
44. Fisher B, Dignam J, Bryant J et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 1996;88:1529-1542.
45. Fisher B, Dignam J, Bryant J et al. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 2001;93:684-690.
46. Abrams JS. Tamoxifen: five versus ten years - is the end in sight? J Natl Cancer Inst 2001;93:662-664.
47. Gail MH, Costantino J, Bryant JP et al. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst 1999;91:1829-1846.